Top worldwide anti-rheumatics by revenue 2017 and 2024

This statistic displays the top anti-rheumatics worldwide by revenue in 2017 and a projection for 2024. Enbrel, a drug developed by Pfizer, Amgen, and Takeda, is expected to generate some four billion U.S. dollars in revenue in 2024. Anti-rheumatic drugs is used to treat and slow the progress of rheumatoid arthritis. Rheumatoid arthritis is an autoimmune disease that principlally attacks the joints but also impacts tissues and organs.

Anti-rheumatic products

Some of the top anti-rheumatic products in the world include J&J, Merck & Co., and Mitsubishi’s Remicade, which generated 8.1 billion U.S. dollars in revenue in 2016 and is expected to decrease to 2.7 billion U.S. dollars by 2022. This drug accounted for over 15 percent of the global market in 2016. Remicade is a trade name for infliximab, an antibody used in the treatment of autoimmune diseases. It is marketed under the name Remicade in the United States and cost between 19,000 and 22,000 per year for patients. Merck & Co. markets this product as Schering-Plough in other regions. Merck & Co. generated 1.7 billion U.S. dollars in their oncology segment in 2016. Remicade works by targeting tumor necrosis factor alpha and inhibiting its activity, but unlike similar rheumatic products like Humira, it is a monoclonal antibody.

Rheumatic diseases include conditions that affect the joints and connective tissue. Arthritis and gout are some of the more common types of this autoimmune disease. Osteoarthritis is one of the most common types of arthritis in the United States, it is characterized by the destruction of cartilage and bone. In Canada, 4.8 million adults over 15 reported that they had been diagnosed with arthritis.

Top anti-rheumatic products based on global revenue in 2017 and 2024

Product (Company)20172024
---
---
---
---
---
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

June 2018

Region

Worldwide

Survey time period

as of May 2018

Supplementary notes

* Projected.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Top pharmaceutical drugs"

Further Content: You might find this interesting as well

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.